Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP).
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D006145:Guanethidine / Q000494:pharmacology; D006168:Guinea Pigs; D006213:Hallucinogens / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006325:Heart Atria / Q000187:drug effects; D066298:In Vitro Techniques; D008784:Methysergide / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011817:Rabbits; D012701:Serotonin / Q000494:pharmacology; D014439:Tyramine / Q000494:pharmacology; D014630:Vagus Nerve / Q000187:drug effects / Q000502:physiology
D006213:Hallucinogens; D010656:Phenylephrine; D012701:Serotonin; D009538:Nicotine; D000661:Amphetamine; D009638:Norepinephrine; D014439:Tyramine; D008784:Methysergide; D004837:Epinephrine; D010646:Phentolamine; D006145:Guanethidine